

=> d que 120

```

L1      1 SEA FILE=REGISTRY ABB=ON PLU=ON "GLUCOSAMINE SULFATE"/CN
L2      215 SEA FILE=REGISTRY ABB=ON PLU=ON 3416-24-8/CRN
L3      22760 SEA FILE=REGISTRY ABB=ON PLU=ON 7664-93-9/CRN
L4      21 SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND L3
L5      1 SEA FILE=REGISTRY ABB=ON PLU=ON "CITRIC ACID"/CN
L6      7125 SEA FILE=REGISTRY ABB=ON PLU=ON 77-92-9/CRN
L7      1 SEA FILE=REGISTRY ABB=ON PLU=ON "TARTARIC ACID"/CN
L8      6999 SEA FILE=REGISTRY ABB=ON PLU=ON 87-69-4/CRN
L9      1 SEA FILE=REGISTRY ABB=ON PLU=ON "GLUTARIC ACID"/CN
L10     1097 SEA FILE=REGISTRY ABB=ON PLU=ON 110-94-1/CRN
L11     1 SEA FILE=REGISTRY ABB=ON PLU=ON "LACTIC ACID"/CN
L12     2101 SEA FILE=REGISTRY ABB=ON PLU=ON 50-21-5/CRN
L13     1 SEA FILE=REGISTRY ABB=ON PLU=ON "MALIC ACID"/CN
L14     975 SEA FILE=REGISTRY ABB=ON PLU=ON 6915-15-7/CRN
L15     2 SEA FILE=REGISTRY ABB=ON PLU=ON "GLUCONIC ACID"/CN
L16     475 SEA FILE=REGISTRY ABB=ON PLU=ON (133-42-6/CRN OR 526-95-4/CRN
)
L20    32 SEA FILE=HCAPLUS ABB=ON PLU=ON (L1 OR L4) AND (L5 OR L6 OR
      L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR
      L16)

```

=> d 120 ibib ab hitstr 1-32

L20 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:912570 HCAPLUS
 DOCUMENT NUMBER: 139:386381
 TITLE: Composition for the treatment and prevention of
 endothelial dysfunction
 INVENTOR(S): Petrus, Edward J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S.
 Ser. No. 947,674.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003215430	A1	20031120	US 2003-436528	20030514
US 6596708	B1	20030722	US 2001-947674	20010907


PRIORITY APPLN. INFO.: US 2001-947674 A2 20010907

AB This invention relates to a method and compns. for the treatment and prevention of disorders associated with endothelial dysfunction. The compns. for the treatment and prevention of endothelial dysfunction in mammals comprise an anti-inflammatory agent containing acetylsalicylic acid, an amino sugar and a zinc compound, combined with dietary supplements. The amino sugar is selected from a group of glucosamine, glucosamine-HCl, glucosamine sulfate, N-acetylglucosamine and mixts.

IT 546-46-3, Zinc citrate 29031-19-4, Glucosamine sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition for treatment and prevention of endothelial dysfunction)

RN 546-46-3 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (9CI) (CA
 INDEX NAME)



● 3/2 Zn


RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H₂ O₄ S




CM 2

CRN 3416-24-8

CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



L20 ANSWER 2 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757082 HCPLUS

DOCUMENT NUMBER: 139:250342

TITLE: Effervescent glucosamine, chondroitin and MSM formula

INVENTOR(S): Phillips, Cleve Alan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont. of U.S. Ser. No. 648,937, abandoned.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003180389	A1	20030925	US 2003-394380	20030320
PRIORITY APPLN. INFO.:			US 2000-648937	B1 20000825
AB	Disclosed is a composition which acts to protect, maintain and repair connective tissue in mammals. The composition includes glucosamine, chondroitin sulfate and sulfur in an effervescent base as its major elements. The effervescent base includes one or more acids and one or more bases and may also include a starch, a flavoring agent and a coloring agent. The composition can be formed into a tablet or can be granular. The tablet or granular mixture is dissolved in a neutral pH liquid such as water for consumption purposes. Effervescent granules were prepared containing fructose 61.31, glucosamine 7.07, citric acid 7.07, chondroitin 5.66, baking soda 4.72, MSM sulfur 4.72, orange flavor 3.77, ascorbic acid 2.36, vanilla 1.41, silica 0.94, CaCO ₃ 0.94, and riboflavin 0.01 %.			
IT	77-92-9, Citric acid, biological studies 87-69-4, Tartaric acid, biological studies 29031-19-4, Glucosamine sulfate RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (effervescent compns. containing glucosamine and chondroitin and MSM for protecting and repairing connective tissue)			
RN	77-92-9 HCPLUS			
CN	1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)			



RN 87-69-4 HCPLUS
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 29031-19-4 HCPLUS
CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
CMF H₂ O₄ S



CM 2

CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 3 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:633055 HCPLUS
 DOCUMENT NUMBER: 139:148803
 TITLE: Cartilage enhancing food supplements and methods of preparing the same
 INVENTOR(S): Stone, Kevin R.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,432,929.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152642	A1	20030814	US 2002-189664	20020703
US 6391864	B1	20020521	US 1999-338021	19990622
US 6432929	B1	20020813	US 2000-598634	20000621
WO 2004004686	A2	20040115	WO 2003-US20969	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-338021	A2 19990622
			US 2000-598634	A2 20000621
			US 1998-97038P	P 19980819
			US 2002-189664	A 20020703

AB A food supplement, either in the form of a snack bar or a beverage, which contains one or more cartilage enhancing supplements is provided. The cartilage supplements include chondroitin, glucosamine, and hyaluronic acid. The food supplement may addnl. be fortified with cetyl myristoleate. The beverage is a mixture of a juice drink base which may include a water-based fruit flavored juice prepared using a pasteurization process at a relatively high temperature and a cartilage supplement solution which


includes a cartilage supplement prepared at a relatively low temperature. The beverage may be carbonated, non-carbonated or concentrated. The preferred cartilage supplement is glucosamine, preferably associated with a counter ion, more preferably as glucosamine HCl. The supplement also contains vitamin C (ascorbic acid) and calcium hydroxide powder.

IT 77-92-9, Citric acid, biological studies 29031-19-4,
Glucosamine sulfate

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(cartilage enhancing food supplements and methods of preparing the same)

RN 77-92-9 HCPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




L20 ANSWER 4 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:590615 HCPLUS
 DOCUMENT NUMBER: 139:138749
 TITLE: Dietary supplements comprising aminosaccharides for treating pain and inflammation
 INVENTOR(S): Cho, Suk H.
 PATENT ASSIGNEE(S): Melaleuca, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 8 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003143292	A1	20030731	US 2002-39246	20020104
US 6713096	B2	20040330		

PRIORITY APPLN. INFO.: US 2002-39246 20020104
 AB Dietary supplement compns. comprising aminosaccharides, a ginger component and an enzyme, can be used to reduce pain, inflammation, stiffness, and/or discomfort associated with inflammatory conditions such as arthritis. Capsules contained glucosamine-HCl 510.00, calcium citrate 100.00, ginger root extract 75.00, rice flour 56.00, a mixture of fungal protease and protease and papain 70.00, green tea extract 75.00, Mg stearate 10.00, hydroxypropyl cellulose 50.00, and silicon dioxide 6.00 mg.
 IT 29031-19-4, Glucosamine sulfate 439666-12-3
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dietary supplements comprising aminosaccharides for treating pain and inflammation)
 RN 29031-19-4 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H2 O4 S



CM 2

CRN 3416-24-8
 CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



RN 439666-12-3 HCAPLUS


CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxypropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 3416-24-8

CMF C6 H13 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 50-21-5

CMF C3 H6 O3



L20 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:563064 HCAPLUS

DOCUMENT NUMBER: 139:122748

TITLE: Anti-inflammatory composition for the treatment and prevention of endothelial dysfunction

INVENTOR(S): Petrus, Edward J.

PATENT ASSIGNEE(S): Advanced Medical Instruments, USA

SOURCE: U.S., 7 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6596708	B1	20030722	US 2001-947674	20010907
US 2003215430	A1	20031120	US 2003-436528	20030514
PRIORITY APPLN. INFO.:			US 2001-947674	A2 20010907

AB A composition for the treatment and prevention of endothelial dysfunction comprising a therapeutically effective amount of anti-inflammatory agents comprising; acetylsalicylic acid, an amino sugar and a zinc compound
 IT 546-46-3, Zinc citrate 29031-19-4, Glucosamine sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-inflammatory composition for the treatment and prevention of endothelial dysfunction)
 RN 546-46-3 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (9CI) (CA INDEX NAME)




● 3/2 Zn

RN 29031-19-4 HCAPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H₂ O₄ S



CM 2

CRN 3416-24-8
 CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 2003:530151 HCAPLUS
 DOCUMENT NUMBER: 139:296935
 TITLE: Agent for prophylaxis and treatment of urolithiasis
 INVENTOR(S): Orlova, S. V.; Belousova, A. S.; Kuz'micheva, G. M.;
 Belousov, S. R.; Alyaev, Yu. G.; Rappoport, L. M.;
 Rudenko, V. I.; Chaban, N. G.
 PATENT ASSIGNEE(S): Russia
 SOURCE: Russ., No pp. given
 CODEN: RUXXE7
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2205655	C1	20030610	RU 2002-104548	20020222
PRIORITY APPLN. INFO.:			RU 2002-104548	20020222
AB	The invention relates to an agent used in prophylaxis and treatment of urolithiasis. The proposed agent involves a food supplement where vegetable components are combined in the ratio from 1:1 to 3:1 where in addition to the known medicinal lovage (Levisticum) and rosemary it comprises the following raw materials: upright cinquefoil rhizomes, madder roots, common bear berry leaves, field horse-tail herb, knot-grass herb, Orthosiphon staminosus, quercetin and citrus bioflavanoids, mineral components, such as chondroitin sulfate, glucosamine sulfate, potassium citrate and magnesium citrate and vitamins: beta-carotene and pyridoxine being all components are taken in the definite amts. In addition to its diuretic effect, the proposed agent shows antibacterial, anti-inflammatory, stone-loosening, membrane-stabilizing and capillary-strengthening effects.			
IT	7778-49-6, Potassium citrate 7779-25-1, Magnesium citrate 29031-19-4, Glucosamine sulfate RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (agent for prophylaxis and treatment of urolithiasis)			
RN	7778-49-6 HCAPLUS			
CN	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium salt (9CI) (CA INDEX NAME)			



●x K

RN 7779-25-1 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (9CI) (CA INDEX NAME)



●x Mg


RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H₂ O₄ S




CM 2

CRN 3416-24-8

CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



L20 ANSWER 7 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:511160 HCPLUS

DOCUMENT NUMBER: 139:63365

TITLE: Use of hyperforin or St. John's wort extracts for the treatment of anaphylactic shock and for maintaining and improving bone health

INVENTOR(S): Werz, Oliver; Albert, Dana; Steinhilber, Dieter; Bock, Andreas

PATENT ASSIGNEE(S): Phenion GMBH & Co. KG, Germany

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053456	A1	20030703	WO 2002-EP14207	20021213
W: AU, BR, BY, CA, CN, DZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, RU, SG, UA, US, UZ, VN, YU, ZA				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
DE 10163676	A1	20030710	DE 2001-10163676	20011221

PRIORITY APPLN. INFO.: DE 2001-10163676 A 20011221


AB The invention discloses the use of hyperforin or St. John's wort (*hypericum*) exts. for the prophylaxis and/or therapy of anaphylactic shock and for maintaining and improving bone health, particularly for treating osteoporosis, and as a nutritional supplement and for pharmaceutical preps. containing hyperforin or St John's wort extract

IT 50-21-5, Lactic acid, biological studies 29031-19-4,
Glucosamine sulfate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(hyperforin or St. John's wort exts. for treatment of anaphylactic
shock and for maintaining and improving bone health)

RN 50-21-5 HCPLUS

CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:472353 HCAPLUS
 DOCUMENT NUMBER: 139:41821
 TITLE: Glucosamine organic acid adducts
 INVENTOR(S): Fosdick, Lawrence E.; Bauer, Timothy W.; Bohlmann, John A.; Hwang, Kioh; Rogers, Brent D.
 PATENT ASSIGNEE(S): Cargill, Incorporated, USA
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049696	A2	20030619	WO 2002-US39309	20021206
WO 2003049696	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-339004P P 20011207

AB The invention pertains to dietary supplement compns. containing glucosamine organic acid adducts (GOA), methods of making such compns. and methods of using such compns. GOA is prepared by partial crystallization, demonstrating the

ability to use the relative solubilities of glucosamine and the organic acid in controlling the product composition, or by surface crystallization in which a solution

of one component, e.g., an organic acid, is sprayed onto the other component in solid form, followed by moisture removal. GOA has tabletting characteristics similar to glucosamine. For example, 1 mol glucosamine hydrochloride was dissolved in 1 L of water and 2 mol of citric acid were added creating a 1:2 glucosamine-citric acid ratio. To this solution 1 mol of NaOH was slowly added and mixed at room temperature. The solution was placed in

a rotary evaporator under vacuum at 60° until 50-70% of the water evaporated resulting in formation of crystals. Crystals were isolated by vacuum filtration and dried in open pans at room temperature

IT 439666-12-3 544455-21-2 544455-22-3

544455-23-4 544455-25-6 544455-26-7

544455-27-8 544455-28-9 544455-29-0

544455-30-3 544455-31-4

RL: FFD (Food or feed use); FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (preparation of glucosamine organic acid adducts as dietary supplement or food ingredient)

RN 439666-12-3 HCPLUS


CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxypropanoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 3416-24-8

CMF C6 H13 N 05


Absolute stereochemistry. Rotation (+).



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 544455-21-2 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 3416-24-8


CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-92-9
 CMF C6 H8 O7




RN 544455-22-3 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (3:1)
 (9CI) (CA INDEX NAME)

CM 1


CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-92-9
 CMF C6 H8 O7




RN 544455-23-4 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
 (9CI) (CA INDEX NAME)


CM 1

CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 77-92-9
CMF C6 H8 O7RN 544455-25-6 HCPLUS
CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2)
(9CI) (CA INDEX NAME)


CM 1

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 77-92-9
CMF C6 H8 O7RN 544455-26-7 HCPLUS
CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:5)
(9CI) (CA INDEX NAME)

CM 1


CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-92-9
 CMF C6 H8 O7




RN 544455-27-8 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:3)
 (9CI) (CA INDEX NAME)

CM 1


CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-92-9
 CMF C6 H8 O7



RN 544455-28-9 HCPLUS


CN D-Glucose, 2-amino-2-deoxy-, bis(2-hydroxypropanoate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 3416-24-8

CMF C6 H13 N O5


Absolute stereochemistry. Rotation (+).



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 544455-29-0 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, hydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 6915-15-7

CMF C4 H6 O5




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




RN 544455-30-3 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, hydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 6915-15-7

CMF C4 H6 O5




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



RN 544455-31-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, hydroxybutanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 6915-15-7


CMF C4 H6 O5



CM 2

CRN 3416-24-8
 CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).




IT 29031-19-4, Glucosamine sulfate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of glucosamine organic acid adducts as dietary supplement or
 food ingredient)

RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H2 O4 S



CM 2

CRN 3416-24-8
 CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).




L20 ANSWER 9 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:352147 HCPLUS
 DOCUMENT NUMBER: 138:343925
 TITLE: Storage-stable poultices containing glucosamine
 INVENTOR(S): Hamamoto, Hidetoshi; Ueda, Aki
 PATENT ASSIGNEE(S): Teikoku Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF


DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003128557	A2	20030508	JP 2001-317930	20011016
PRIORITY APPLN. INFO.:			JP 2001-317930	20011016
AB	The poultices, useful for treatment of inflammation, etc., contain glucosamine and crosslinked hydrogels showing pH ≤ 5 and containing water-soluble polymers, H ₂ O, crosslinking agents, and pH adjusters. Glucosamine HCl salt 4.0, poly(acrylic acid) 5.0, Na polyacrylate 5.0, CM-cellulose 2.0, gelatin 0.4, poly(vinyl alc.) 0.1, Na edetate 0.1, kaolin 2.0, glycerin 20.0, sorbitol solution 10.0, Al(OH) ₃ 0.2, AlCl ₃ 0.1, malic acid 3.0, tartaric acid 1.0, Polysorbate 80 0.1, castor oil 1.0, methylparaben 0.2, and H ₂ O to 100 weight% were mixed and applied on a nonwoven fabric to give a poultice, which showed no discoloration during storage for 6 mo.			
IT	87-69-4, Tartaric acid, biological studies 6915-15-7, Malic acid RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pH adjuster; storage-stable poultices containing glucosamine and crosslinked hydrogels)			
RN	87-69-4 HCPLUS			
CN	Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




RN 6915-15-7 HCPLUS
 CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)



IT 29031-19-4, Glucosamine sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (storage-stable poultices containing glucosamine and crosslinked hydrogels)
 RN 29031-19-4 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H₂ O₄ S



CM 2

CRN 3416-24-8
CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



L20 ANSWER 10 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:282111 HCPLUS
 DOCUMENT NUMBER: 138:286531
 TITLE: Nutritional compositions, kits, and methods for promoting defined health benefits
 INVENTOR(S): Kern, Kenneth norman; Heisey, Matthew Thomas
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 586,213, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003069202	A1	20030410	US 2001-760280	20010112
WO 2001093847	A2	20011213	WO 2001-US17714	20010601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1289510	A2	20030312	EP 2001-946030	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003535126	T2	20031125	JP 2002-501420	20010601
PRIORITY APPLN. INFO.:			US 2000-586213	B2 20000602
			US 2001-760280	A 20010112

WO 2001-US17714 W 20010601

- AB The present invention is directed to compns. comprising: (a) a first component selected from the group consisting of gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixts. thereof; and (b) a second component comprising: (i) a cation source selected from the group consisting of calcium, potassium, magnesium, and mixts. thereof; and (ii) an edible acid source. The present invention is further directed to food, beverage, pharmaceutical, over-the-counter, and dietary supplement products, which comprise the present compns. The invention also relates to kits comprising the present compns. and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention addnl. relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.
- IT 50-21-5, Lactic acid, biological studies 77-92-9, Citric acid, biological studies 87-69-4, Tartaric acid, biological studies 526-95-4, Gluconic acid 6915-15-7, Malic acid 29031-19-4, Glucosamine sulfate 142606-53-9
433685-09-7
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional compns., kits, and methods for promoting defined health benefits)
- RN 50-21-5 HCPLUS
CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




- RN 77-92-9 HCPLUS
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




- RN 87-69-4 HCPLUS
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 526-95-4 HCAPLUS
 CN D-Gluconic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 6915-15-7 HCAPLUS
 CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)



RN 29031-19-4 HCAPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H₂ O₄ S



CM 2

CRN 3416-24-8
 CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).




RN 142606-53-9 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, calcium salt, mixt. with hydroxybutanedioic acid calcium salt (9CI) (CA INDEX NAME)

CM 1

Krishnan 09/926, 821

June 25, 2004


CRN 17482-42-7
CMF C4 H6 O5 . x Ca



●x Ca

CM 2

CRN 7693-13-2
CMF C6 H8 O7 . x Ca




●x Ca

RN 433685-09-7 HCPLUS
CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt), potassium salt (9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 11 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:736725 HCPLUS

DOCUMENT NUMBER: 137:268432

TITLE: Solid-dosage forms for weight loss product

INVENTOR(S): Fleischner, Albert M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002136782	A1	20020926	US 2001-761622	20010118
US 6420350	B1	20020716	US 2001-928715	20010813

PRIORITY APPLN. INFO.: US 2001-761622 A2 20010118

AB Supplement compns. designed to support weight loss and increase energy are disclosed. The compns., to support weight loss and increase energy, comprise vitamin B6, zinc, manganese, chromium, Gymnema sylvestre leaf and extract, vanadium, glucosamine sulfate, lipotropic blend, appetite control blend, and thermogenic herbal concs. The compns. can be used in capsules or tablets.


IT 546-46-3, Zinc citrate 29031-19-4, Glucosamine sulfate

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid-dosage forms for weight loss product)

RN 546-46-3 HCPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (9CI) (CA INDEX NAME)




● 3/2 Zn

RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9

CMF H₂ O₄ S

CM 2

CRN 3416-24-8
CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



L20 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:693120 HCAPLUS
 DOCUMENT NUMBER: 137:210995
 TITLE: Neutrophil function inhibitors which contain glucosamine
 INVENTOR(S): Nagaoka, Isao; Sakamoto, Koji
 PATENT ASSIGNEE(S): Dainichiseika Color & Chemicals Mfg. Co. Ltd., Japan
 SOURCE: Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1238669	A2	20020911	EP 2001-116700	20010717
EP 1238669	A3	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002265365	A2	20020918	JP 2001-64646	20010308
NO 2001003535	A	20020909	NO 2001-3535	20010717
US 2002128230	A1	20020912	US 2001-906771	20010718
US 6627621	B2	20030930		
CN 1374086	A	20021016	CN 2001-125453	20010718

PRIORITY APPLN. INFO.: JP 2001-64646 A 20010308
 AB Glucosamine salts are effective for the inhibition of neutrophil functions, and hence, are useful for the prevention and/or treatment of diseases, caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, such as respiratory disease syndrome and adult respiratory disease syndrome. Use of glucosamine salts can, therefore, provide neutrophil function inhibitors,

preventives and/or remedies for diseases caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, and also methods for the prevention and/or treatment of such diseases. Glucosamine hydrochloride inhibited in a concentration dependent

manner (0.01-1 mM) the formation of active oxygen by N-formyl-1-methionyl-1-leucyl-1-phenylalanine or opsonized zymosan.

IT 29031-19-4, Glucosamine sulfate 457048-78-1

457048-79-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neutrophil function inhibitors which contain glucosamine)


RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



RN 457048-78-1 HCPLUS


CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 3416-24-8

CMF C6 H13 N 05


Absolute stereochemistry. Rotation (+).



CM 2

CRN 77-92-9
CMF C6 H8 O7RN 457048-79-2 HCAPLUS
CN D-Glucose, 2-amino-2-deoxy-, hydroxybutanedioate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 6915-15-7
CMF C4 H6 O5

CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:688479 HCAPLUS
 DOCUMENT NUMBER: 137:222055
 TITLE: A dietary supplement containing calcium and vitamin D
 for promoting healthy bone structure

INVENTOR(S): Krumhar, Kim C.; Johnson, Holly A.
PATENT ASSIGNEE(S): Metagenics, Inc., USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6447809	B1	20020910	US 2000-568903	20000511
US 2003059481	A1	20030327	US 2002-241616	20020909
PRIORITY APPLN. INFO.:			US 1999-133603P	P 19990511
			US 2000-568903	A1 20000511


AB A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcryst. hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement. For example, tablets contained microcryst. hydroxyapatite 1000 mg, cholecalciferol 200 IU, ipriflavone (an osteoblast stimulant) 200 mg, dicalcium phosphate 700 mg, and a source of magnesium 200 mg.

IT 77-92-9D, Citric acid, boron complexes 527-09-3, Copper gluconate 546-46-3, Zinc citrate 869-06-7, Magnesium malate 7779-25-1, Magnesium citrate 29031-19-4, Glucosamine sulfate


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral dietary supplement containing calcium source, vitamin D, and
ipriflavone for promoting healthy bone structure)

RN 77-92-9 HCAPLUS

CN 1,2,3-*Propanetricarboxylic acid, 2-hydroxy-* (9CI) (CA INDEX NAME)




RN 527-09-3 HCAPLUS
CN Copper, bis(D-gluconato- κ O1, κ O2) - (9CI) (CA INDEX NAME)



RN 546-46-3 HCAPLUS


CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3) (9CI) (CA INDEX NAME)



● 3/2 Zn

RN 869-06-7 HCAPLUS


CN Butanedioic acid, hydroxy-, magnesium salt (1:1) (9CI) (CA INDEX NAME)



● Mg

RN 7779-25-1 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt (9CI) (CA INDEX NAME)




● x Mg

RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9

CMF H₂ O₄ S

CM 2

CRN 3416-24-8
 CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:503626 HCPLUS

DOCUMENT NUMBER: 137:62507

TITLE: Compositions containing *Withania somnifera* Dunal and glucosamine and food, feed, and drugs containing the compositions

INVENTOR(S): Kameyama, Hiroshi; Maesaki, Yuji

PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan; Nippon Kayaku Food Techno K. K.

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002187846	A2	20020705	JP 2001-279650	20010914

PRIORITY APPLN. INFO.: JP 2000-311779 A 20001012

AB Compns. containing *W. somnifera* and glucosamine (I) and foods, feeds, antiarthritics, and antirheumatics containing the compns. are claimed. *W. somnifera* may be used as exts. of the root containing withaferin A, sitoindosides, and withanolides. Simultaneous administration of tablets of *W. somnifera* extract and I HCl tablets to volunteers having subjective symptoms of arthritis or rheumatoid arthritis for 4 wk significantly relieves the symptoms. Capsules, granules, tablets, etc., containing the extract

and I HCl or sulfate were also manufactured

IT 29031-19-4, Glucosamine sulfate 439666-12-3


RL: FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiarthritic and antirheumatic compns. containing *Withania somnifera* and glucosamine)

RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9

CMF H₂ O₄ S

CM 2

CRN 3416-24-8
CMF C₆ H₁₃ N O₅


Absolute stereochemistry. Rotation (+).

RN 439666-12-3 HCPLUS
CN D-Glucose, 2-amino-2-deoxy-, 2-hydroxypropanoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 3416-24-8
CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).




CM 2

CRN 50-21-5
CMF C₃ H₆ O₃

L20 ANSWER 15 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:429542 HCPLUS
 DOCUMENT NUMBER: 137:11003
 TITLE: Chondroprotective/restorative compositions containing
 hyaluronic acid
 INVENTOR(S): Pierce, Scott W.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068718	A1	20020606	US 2001-967977	20011002
			US 2000-237838P	P 20001003
PRIORITY APPLN. INFO.:				
AB An oral composition based on hyaluronic acid or its salts and optionally a therapeutic drug is provided for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, and the reduction or inhibition of the production of hyaluronic acid in a mammal.				
Addnl., compns. containing hyaluronic acid, chondroitin sulfate and glucosamine sulfate in a paste formulation are also described which can be administered on their own or can be used as a feed additive for cats and dogs. For example, a composition contained (by weight) glucosamine sulfate 36%, chondroitin sulfate 4%, sodium hyaluronate 0.144%, manganese sulfate 0.144%, ibuprofen 200 mg, powdered sugar 20%, glycerin 0.7%, xanthan gum 0.2%, sodium benzoate 0.7%, citric acid 0.2%, molasses 23.5%, and water 14.4%.				
IT 29031-19-4, Glucosamine sulfate RL: FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)				
RN 29031-19-4 HCPLUS CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)				
CM 1				
CRN 7664-93-9 CMF H2 O4 S				




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




IT 50-21-5, Lactic acid, biological studies 51-42-3,
 Epinephrine bitartrate 68-04-2, Sodium citrate 77-92-9
 , Citric acid, biological studies 143-71-5, Hydrocodone
 bitartrate 7054-25-3, Quinidine gluconate 18472-51-0,
 Chlorhexidine gluconate 56392-17-7, Metoprolol tartrate
 88637-37-0, Diphenhydramine citrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (chondroprotective/restorative compns. containing hyaluronic acid for
 treatment of joint disorders)

RN 50-21-5 HCPLUS

CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 51-42-3 HCPLUS


CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-,
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




CM 2


CRN 51-43-4

CMF C9 H13 N O3

Absolute stereochemistry. Rotation (-).




RN 68-04-2 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt (9CI) (CA INDEX NAME)



●3 Na

RN 77-92-9 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 143-71-5 HCAPLUS
 CN Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-,
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 125-29-1
 CMF C18 H21 N O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 7054-25-3 HCPLUS

CN D-Gluconic acid, compd. with (9S)-6'-methoxycinchonan-9-ol (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 526-95-4
CMF C6 H12 O7


Absolute stereochemistry.



CM 2

CRN 56-54-2
CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).




RN 18472-51-0 HCPLUS

CN D-Gluconic acid, compd. with N,N''-bis(4-chlorophenyl)-3,12-diimino-
2,4,11,13-tetraazatetradecanediamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 526-95-4
CMF C6 H12 O7

Absolute stereochemistry.




CM 2

CRN 55-56-1
CMF C22 H30 Cl2 N10

RN 56392-17-7 HCAPLUS

CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 51384-51-1
CMF C15 H25 N O3

CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 88637-37-0 HCPLUS

CN Ethanamine, 2-(diphenylmethoxy)-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 77-92-9

CMF C6 H8 O7



CM 2

CRN 58-73-1

CMF C17 H21 N O

Ph₂CH—O—CH₂—CH₂—NMe₂

L20 ANSWER 16 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:408783 HCPLUS

DOCUMENT NUMBER: 137:2412

TITLE: Petunia hybrida gene Shooting encoding cytokinin biosynthesis enzyme tRNA-IPT and uses in plant growth regulation and cosmetic preparations

INVENTOR(S): Meyer, Peter; Zubko, Elena

PATENT ASSIGNEE(S): University of Leeds, UK

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042440	A2	20020530	WO 2001-GB5175	20011126
WO 2002042440	A3	20021017		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002023877 A5 20020603 AU 2002-23877 20011126
 EP 1414951 A2 20040506 EP 2001-997545 20011126
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004117871 A1 20040617 US 2003-432534 20030702
 PRIORITY APPLN. INFO.: GB 2000-28827 A 20001125
 GB 2001-971 A 20010113
 GB 2001-23970 A 20011005
 WO 2001-GB5175 W 20011126


AB The present invention provides a naturally occurring plant gene encoding a cytokinin (CK) biosynthesis enzyme. In an activation tagging experiment a Petunia hybrida line was identified that showed CK-specific effects including control of cellular processes such as plant growth, enhanced shooting, reduced apical dominance and delayed senescence and flowering. This phenotype correlated with the enhanced expression of a gene we labeled Shooting (Sho). The petunia "Shooting" gene, which encodes a homolog to Arabidopsis thaliana transfer ribonucleate-isopentenyltransferase (tRNA-IPT)-like proteins, also causes CK-specific effects when expressed in other plant species. In contrast to the ipt gene from Agrobacterium, which primarily increases CK zeatin levels, Shooting expression in petunia and tobacco especially enhances the levels of certain N6-(Δ2-isopentenyl) adenosine (2iP) derivs. The present invention provides Petunia Shooting gene and protein sequences and uses therefor and control thereof in the production of plants and/or plant cells that are capable of exhibiting a variety of advantageous characteristics associated with CK regulated processes. A further aspect of the invention there is provided use as a cosmetic to reduce the signs of skin ageing the plant extract which includes a transcriptionally activated/activatable form of the Shooting.

IT 50-21-5, biological studies 29031-19-4, Glucosamine sulfate

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (cosmetic preparation further comprising; petunia gene Shooting encoding CK biosynthesis enzyme tRNA-IPT and plant growth regulation and cosmetic preps.)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9


CMF H2 O4 S




CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



IT 72-17-3, Sodium lactate
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (petunia gene Shooting encoding CK biosynthesis enzyme tRNA-IPT and
 plant growth regulation and cosmetic preps.)
 RN 72-17-3 HCPLUS
 CN Propanoic acid, 2-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L20 ANSWER 17 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:158383 HCPLUS
 DOCUMENT NUMBER: 136:205508
 TITLE: Collagen-based composition and method for growing,
 protecting, and healing tissues and cells
 Petito, George D.; Petito, Anita M.
 INVENTOR(S):
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.
 Ser. No. 360,169.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002025921	A1	20020228	US 2001-983274	20011023

US 6476005	B1	20021105	US 1999-360169	19990726
WO 2003034993	A2	20030501	WO 2002-US33724	20021023
WO 2003034993	A3	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003212005	A1	20031113	US 2003-457599	20030610
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.:
 US 1999-360169 A2 19990726
 US 1998-46710 B2 19980324
 US 2001-983274 A 20011023

AB A composition and method for facilitating the growth, protection and healing of tissues and cells in animals and humans are described. The composition is formulated as either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or sponge, sprayable solution, topically applied patch with adhesive and reservoir system, an intermediate for coatables such as films and bandages, a matrix for membranes, or as a matrix of flexible polymer(s), or delivered as an oral liquid, tablet or capsule. The main ingredients are hydrolyzed Type I collagen having a mol. weight of 1000-10,000, polysulfated glycosaminoglycans, a hyaluronic acid salt, a glucosamine salt, and optionally, a chelated manganese ascorbate and L-malic acid. In the topical form, the composition is administered to the cleaned wound site where it absorbs exudate, provides a phys. barrier to bacterial infestation, reduces pain, and expedites wound healing by having chemotactic, hemostatic, bacteriostatic, and other therapeutic benefits. Scars are advantageously reduced. For example, a diabetic patient with an advanced wound of a 14 yr old graft site in area from amputation of 15% of one infected foot received weekly applications of biodegradable hydrolyzed collagen in powder and gel form absent preservatives or alcs. The wound healed in 27 days.

IT 29031-19-4, Glucosamine sulfate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. based on hydrolyzed collagen, glycosaminoglycans, and hyaluronic acid or glucosamine salt for growing, protecting, and healing tissues and cells)


RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9


CMF H2 O4 S



CM 2

CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




IT 77-92-9, Citric acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. based on hydrolyzed collagen, glycosaminoglycans, and
 hyaluronic acid or glucosamine salt for growing, protecting, and
 healing tissues and cells)

RN 77-92-9 HCPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L20 ANSWER 18 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:143204 HCPLUS

DOCUMENT NUMBER: 136:189383

TITLE: A water-free transdermal delivery system

INVENTOR(S): Dransfield, Charles William

PATENT ASSIGNEE(S): Australia

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002022052	A1	20020221	US 2001-863764	20010524
PRIORITY APPLN. INFO.:			AU 2000-6691	A 20000406
			AU 2000-8885	A 20000721

AB A transdermal or transepithelial composition substantially free of water comprises a biol. active agent in the form of microfined particles, sized less than 2 μ down to less than 0.1 μ , which by massage pressure are mech. entrained within the interstices of the stratum corneum. Particles < 0.5 μ do not require a carrier for entrainment. Delivery into mucosal epithelia is obtained by particles < 1 μ with delivery increasing with decreasing particle size. For example, in order to demonstrate the present invention, two compns. containing ibuprofen as the


active agent were prepared. Particles in both samples were identical (< 0.5 μm). However, sample A was water-free, while sample B contained 10% water. Transdermal absorption of the ibuprofen preps. were compared using fresh bovine udder skin mounted on Franz diffusion cells at 37°. Approx. 30 mg of the ibuprofen preparation was applied to the skin and massaged into the skin using a vibratory massager. The water free sample (A) demonstrated a higher rate of absorption in less time than a similar formulation containing 10% water (sample B). In sample B the delivery was more than halved and the time rate of the delivery was found to be greatly reduced with delivery curve showing 16% over 12 h and only a further 7.5% delivery over the next 12 h.

IT 6915-15-7, Malic acid 29031-19-4, Glucosamine sulfate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-free transdermal and transepithelial drug delivery systems)

RN 6915-15-7 HCAPLUS

CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).




L20 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:142489 HCAPLUS
DOCUMENT NUMBER: 136:189363

TITLE: Preparation of tablet compositions
 INVENTOR(S): Mergens, William J.; Chang, Kuei Tu; Holly, Gerald T.
 PATENT ASSIGNEE(S): Rexall Sundown, Inc., USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013793	A2	20020221	WO 2001-US20965	20010702
WO 2002013793	A3	20020815		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
US 6358526	B1	20020319	US 2000-639780	20000816
AU 2001073122	A5	20020225	AU 2001-73122	20010702
EP 1309314	A2	20030514	EP 2001-952362	20010702
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
BR 2001013305	A	20030715	BR 2001-13305	20010702
JP 2004506007	T2	20040226	JP 2002-518940	20010702
US 2002150617	A1	20021017	US 2002-59759	20020129
PRIORITY APPLN. INFO.:			US 2000-639780	A 20000816
			WO 2001-US20965	W 20010702

- AB The present invention provides a method of making tablet compns. that are substantially free of excipients. The method includes forming a compactable granular mixture containing at least one compaction enhancing therapeutic compound, at least 1 other drug, that is different from the compaction enhancing drug, and <15% a non-aesthetic excipient. The compactable granular mixture thus obtained is compressed to form a tablet composition. The present invention also provides tablet compns. produced by the methods of the present invention that are substantially free of excipients. Tablets containing 470.59 mg chondroitin, 526.35 mg PVP-granulated glucosamine, and 3.75 mg magnesium stearate were prepared. The PVP-granulated glucosamine contained 93 % glucosamine and 5% PVP. The tablets were evaluated for disintegration time, hardness, and friability.
- IT 7693-13-2, Calcium citrate 29031-19-4, Glucosamine sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of tablet compns.)
- RN 7693-13-2 HCPLUS
- CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, calcium salt (9CI) (CA INDEX NAME)



●x Ca


RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:903816 HCAPLUS

DOCUMENT NUMBER: 136:42843

TITLE: Compositions, kits, and methods for promoting defined health benefits

INVENTOR(S): Kern, Kenneth Norman; Heisey, Matthew Thomas

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.

KIND DATE

APPLICATION NO. DATE


WO 2001093847	A2	20011213	WO 2001-US17714	20010601
W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003069202	A1	20030410	US 2001-760280	20010112
EP 1289510	A2	20030312	EP 2001-946030	20010601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003535126	T2	20031125	JP 2002-501420	20010601
PRIORITY APPLN. INFO.:			US 2000-586213	A 20000602
			US 2001-760280	A 20010112
			WO 2001-US17714	W 20010601

- AB The present invention is directed to compns. comprising: (a) a first component selected from the group consisting of gelatin, cartilage, amino sugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts and mixts.; and (b) a second component comprising a cation source selected from the group consisting of calcium, potassium, magnesium, and mixts. and an edible acid source. The present invention is further directed to food, beverage, pharmaceutical, over-the-counter, and dietary supplement products, which comprise the present compns. The invention also relates to kits comprising the present compns. and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention addnl. relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein. Thus, hard lemon candies are prepared by combining the following components as indicated: sugar 200, light corn syrup 63, water 60, lemon flavor glucosamine-HCl 16, and calcium citrate malate 14.9 g.
- IT 77-92-9, Citric acid, biological studies 87-69-4,
Tartaric acid, biological studies 526-95-4, Gluconic acid
29031-19-4, Glucosamine sulfate 216699-44-4
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and kits for promoting defined health benefits)
- RN 77-92-9 HCPLUS
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 87-69-4 HCPLUS
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 526-95-4 HCAPLUS
 CN D-Gluconic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 29031-19-4 HCAPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H₂ O₄ S



CM 2

CRN 3416-24-8
 CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



RN 216699-44-4 HCAPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt), compd. with potassium chloride (KCl) (2:1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 7447-40-7
 CMF Cl K


Cl-K

CM 2

CRN 14999-43-0
 CMF C6 H13 N O5 . 1/2 H2 O4 S

CM 3


CRN 7664-93-9
 CMF H2 O4 S



CM 4

CRN 3416-24-8
 CMF C6 H13 N O5


Absolute stereochemistry. Rotation (+).



L20 ANSWER 21 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:185507 HCPLUS
 DOCUMENT NUMBER: 134:192559
 TITLE: Food product containing health-improving agents for
 pets and process for manufacturing same
 INVENTOR(S): Hodge, Jason; Richardson, Louise; Stoodley, Neil;
 Giffard, Catriona; Collins, Stella
 PATENT ASSIGNEE(S): Effem Foods Pty. Ltd., Australia
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001017364	A1	20010315	WO 2000-AU1055	20000906
WO 2001017364	C2	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1229802	A1	20020814	EP 2000-960230	20000906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508069	T2	20030304	JP 2001-521166	20000906
NZ 517941	A	20030829	NZ 2000-517941	20000906
AU 1999-2665 A 19990906 AU 2000-5182 A 20000120 WO 2000-AU1055 W 20000906				

- PRIORITY APPLN. INFO.:
- AB This invention is concerned with packaged food products which contain specific combinations of functional additives aimed at addressing specific health indicators, in particular flatulence, gastro-intestinal health, stress and immune system responsiveness, in pet animals. There is provided a com. packaged mammal pet food product that includes a manufactured, shelf-stable food substrate and a combination of functional additives. The functional additives include at least one non-palatable plant-based remedy and/or dietary fiber source that are present to strengthen and/or maintain a specified health indicator of a mammal pet animal. The food product is portioned and packaged with the functional additives being present in predtd. concns. and amts. sufficient to be effective in achieving said indications on regular feeding of the pet animal with said food product. The food substrate is present in a proportion sufficient to mask the flavor and/or odor of the non-palatable additive and comprises a unique combination of materials that are able to be processed at lower temps. to preserve the natural botanical functional additive's activity. Functional additives intended to address dietary flatulence problems include a combination of Yucca extract, charcoal and salts of zinc, such as zinc acetate. Functional additives to promote or maintain gastrointestinal health include a combination of L-glutamine, D-glucosamine sulfate, sugar beet pulp, slippery elm. Functional additives to strengthen or maintain a pet animal's natural body defenses include a combination of vitamin E, vitamin B complex, primrose oil, vitamin C and Marigold meal. Functional additives to promote or maintain reduction of stress and/or improved behavior of a pet animal include a combination of Valerian root extract, Kava root extract, vitamin B complex and magnesium salt.
- IT 77-92-9, Citric acid, biological studies 29031-19-4,
D-Glucosamine sulfate
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(feed product containing health-improving agents for pets and process for manufacturing same)
- RN 77-92-9 HCAPLUS
- CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:31337 HCAPLUS

DOCUMENT NUMBER: 134:91157

TITLE: A formulation of glucosamine sulfate

INVENTOR(S): Maier, Hans

PATENT ASSIGNEE(S): Greither, Peter, Switz.

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001993 W: CA, US	A1	20010111	WO 1999-CH291	19990702

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRIORITY APPLN. INFO.: WO 1999-CH291 19990702


AB A storage-stable formulation of glucosamine sulfate or a mixed salt thereof, comprising a fruit acid. In a preferred embodiment, the fruit acid, preferably citric acid, is provided in an amount roughly equal to glucosamine sulfate.

IT 77-92-9, Citric acid, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of glucosamine sulfate)

RN 77-92-9 HCPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



IT 29031-19-4, Glucosamine sulfate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of glucosamine sulfate)


RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:31336 HCAPLUS
 DOCUMENT NUMBER: 134:91156
 TITLE: A solid formulation of glucosamine sulfate
 INVENTOR(S): Maier, Hans; Parekh, Harish
 PATENT ASSIGNEE(S): SCA Lohnherstellungs A.-G., Switz.; Pharma Base S.A.
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001992	A1	20010111	WO 1999-CH289	19990702
W: CA, US				
PRIORITY APPLN. INFO.:			WO 1999-CH289	19990702
AB An effervescent preparation of glucosamine sulfate or a mixed salt thereof, suitable for preparing a drinkable medicine and applying a patient's daily dosage in a single dose. In a preferred embodiment of the invention, the preparation comprises a fruit acid, preferably citric acid, as acid component and for the improvement of storage-stability. A further preferred dosage form are effervescent tablets.				
IT	77-92-9, Citric acid, biological studies			
	RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(solid formulation of glucosamine sulfate)			
RN	77-92-9 HCAPLUS			
CN	1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)			



IT 29031-19-4, Glucosamine sulfate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solid formulation of glucosamine sulfate)
 RN 29031-19-4 HCAPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H2 O4 S



CM 2

CRN 3416-24-8
 CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 24 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:911083 HCPLUS
 DOCUMENT NUMBER: 134:55838
 TITLE: Cartilage-enhancing food supplements including snack bars and juice-based beverages
 INVENTOR(S): Stone, Kevin R.
 PATENT ASSIGNEE(S): Joint Juice Incorporated, USA
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078320	A1	20001228	WO 2000-US40267	20000621
W: AU, CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6391864	B1	20020521	US 1999-338021	19990622
EP 1263418	A2	20021211	EP 2000-960108	20000621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003530072	T2	20031014	JP 2001-504383	20000621
PRIORITY APPLN. INFO.:			US 1999-338021	A 19990622
			US 1998-97038P	P 19980819
			WO 2000-US40267	W 20000621


AB A food supplement, either in the form of a snack bar or a beverage, contains one or more cartilage-enhancing supplements, which may include chondroitin, glucosamine, and hyaluronic acid. The food supplement may addnl. be fortified with cetyl myristoleate. The beverage is a mixture of a juice drink base which may include a water-based fruit-flavored juice prepared using a pasteurization process at a relatively high temperature and a cartilage supplement solution which includes a cartilage supplement prepared at a relatively low temperature. The beverage may be carbonated, non-carbonated or concentrated. The preferred cartilage supplement is glucosamine, preferably associated with a counter ion (e.g., glucosamine HCl). Thus, a nutritional bar may contain chondroitin sulfate 1.5, glucosamine sulfate 1.5, hyaluronic acid 1.5, and cetyl myristoleate 1.5%, plus other constituents.

IT 77-92-9, Citric acid, biological studies 29031-19-4,
Glucosamine sulfate

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(cartilage-enhancing food supplements including snack bars and
juice-based beverages)

RN 77-92-9 HCPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 25 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:880946 HCPLUS

DOCUMENT NUMBER: 134:25362

TITLE: Use of catechins for arthritis treatment,
compositions, and screening method

INVENTOR(S): Buttle, David; Adcocks, Clair; Collin, Peter

PATENT ASSIGNEE(S): University of Sheffield, UK

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074662	A2	20001214	WO 2000-GB2048	20000606
WO 2000074662	A3	20020314		
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
EP 1207862	A2	20020529	EP 2000-935346	20000606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003501381	T2	20030114	JP 2001-501199	20000606
PRIORITY APPLN. INFO.:			US 1999-137699P P 19990607	
			GB 2000-7321 A 20000327	
			WO 2000-GB2048 W 20000606	

AB The invention relates to the use of catechins in the treatment of various forms of arthritis, including the use of combinations of catechins and other anti-arthritis agents in the treatment; medicaments and compns. for use in the treatment; and methods to identify agents with anti-arthritis properties.

IT 29031-19-4, Glucosamine sulfate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(catechins for arthritis treatment, compns., and screening method)


RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2


CRN 3416-24-8

CMF C6 H13 N 05

Absolute stereochemistry. Rotation (+).



IT 50-21-5, Lactic acid, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (chondrocyte lactate output; catechins for arthritis treatment,
 compns., and screening method)
 RN 50-21-5 HCAPLUS
 CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



L20 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:65552 HCAPLUS
 DOCUMENT NUMBER: 132:127462
 TITLE: Particles, in particular micro- or nanoparticles, of crosslinked mono- and oligosaccharides, their production, and cosmetic, pharmaceutical, or food compositions containing them
 INVENTOR(S): Perrier, Eric; Rey-Goutenoire, Sylvie; Buffevant, Chantal; Levy, Marie-Christine; Pariot, Nadine; Edwards, Florence; Andry, Marie-Christine
 PATENT ASSIGNEE(S): Coletica, Fr.
 SOURCE: Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19932216	A1	20000127	DE 1999-19932216	19990709
FR 2780901	A1	20000114	FR 1998-8809	19980709
FR 2780901	B1	20000929		
NL 1012517	C2	20000111	NL 1999-1012517	19990705
KR 2000011579	A	20000225	KR 1999-27476	19990708
JP 2000038402	A2	20000208	JP 1999-196705	19990709
JP 3437797	B2	20030818		
US 6197757	B1	20010306	US 1999-350131	19990709
ES 2155793	A1	20010516	ES 1999-1547	19990709
ES 2155793	B1	20011201		
IT 1311514	B1	20020313	IT 1999-T0599	19990709

PRIORITY APPLN. INFO.: FR 1998-8809 A 19980709
 AB Particles consisting of ≥ 1 mono- or oligosaccharide, which are surface-crosslinked in emulsion by esterification of primary OH groups on the saccharides with a polyfunctional acylating agent, are useful as

carriers or encapsulating agents for various hydrophilic or lipophilic active substances in preparation of cosmetic, pharmaceutical, or food compns. The particles are biocompatible, biodegradable, and suitable for stabilization and protection of sensitive active substances or for their sustained release. The crosslinking reaction preferably occurs in a water-in-oil emulsion at room temperature and results in formation of a membrane

of crosslinked saccharide surrounding an aqueous phase. The saccharide may be a cyclodextrin; by forming an inclusion compound with an active substance, it can be used to remove or harvest the latter from a liquid medium, or alternatively can slowly release an active substance from an inclusion compound. Thus, 6 mL of a 10% solution of dihydroxyacetone (a ketose) in 1M carbonate buffer (pH 11) was emulsified in 30 mL cyclohexane containing 5% Span 85, and with continued stirring, 40 mL of a 5% solution of terephthaloyl chloride in CHCl₃-cyclohexane (1:4 by volume); after 30 min, the microcapsules were collected and washed. These microcapsules dissolved slowly in 1% Na₂CO₃ solution or in PEG owing to alcoholysis of the ester bonds; the released dihydroxyacetone reacted with glycine to form a brown color. The microcapsules can therefore be used in cosmetic tanning preps.


IT 526-95-4, D-Gluconic acid 29031-19-4, D-Glucosamine sulfate

RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crosslinked; particles of crosslinked mono- and oligosaccharides, their production, and cosmetic, pharmaceutical, or food compns. containing them)

RN 526-95-4 HCPLUS

CN D-Gluconic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 29031-19-4 HCPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9


CMF H2 O4 S




CM 2

CRN 3416-24-8
 CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



IT 110-94-1D, Glutaric acid, dihalides
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (particles of crosslinked mono- and oligosaccharides, their production, and
 cosmetic, pharmaceutical, or food compns. containing them)
 RN 110-94-1 HCPLUS
 CN Pentanedioic acid (9CI) (CA INDEX NAME)



L20 ANSWER 27 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:561584 HCPLUS
 DOCUMENT NUMBER: 131:175090
 TITLE: Topical compositions containing lecithins and
 moisturizers for the treatment skin disorders
 INVENTOR(S): Crandall, Wilson Trafton
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 9 pp., Cont.-in-part of U.S. 5,639,740.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5945409	A	19990831	US 1997-876764	19970616
US 5639740	A	19970617	US 1995-403241	19950310
AU 9725503	A1	19981020	AU 1997-25503	19970325
WO 9842309	A1	19981001	WO 1998-US5910	19980325
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9867750	A1	19981020	AU 1998-67750	19980325
US 6316428	B1	20011113	US 1999-383779	19990826
PRIORITY APPLN. INFO.:			US 1995-403241	A2 19950310
			WO 1997-US4985	A 19970325
			US 1997-876764	A 19970616
			WO 1998-US5910	W 19980325

AB The present invention comprises methods and compns. for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns. The composition comprises water-dispersible lecithin and compds. selected from the group consisting of elastin, elastin fragments, elastin-glycolic acid, collagen, collagen fragments, yeast exts., skin respiratory factor, glucosamine, glucosamine sulfate, hyaluronic acid, hyaluronate, chondroitin sulfate, cholic acid, deoxycholic acid, ginseng extract, aloe vera powder, aloe vera oil, RNA and DNA fragments, ascorbyl palmitate, ascorbic acid, retinol palmitate, dehydroxycholesterol, vitamin E, vitamin E lineolate, panthenol Et ether, glycerol ceramides, glycogen, DL-pyroglutamic acid, urea, sodium lactate, lactate, glycerin, sorbitol, oils of borage, evening primrose, black currant, almond and canola, vanishing cream, cholesterol, flavonoids, witch hazel, chamomile, parsley, hibiscus, capric and caprylic triglycerides, amino acids, allantoin, sodium, calcium, potassium, phosphate, chloride, sodium lactate, alpha hydroxy acids, cocoa butter, coconut oil, jojoba oil, safflower oil, wheat germ oil, sesame oil, selachyl alc., shark oil, cerebrosides, proanthocyanidin, farnesol, candelilla, carnauba wax, vitamin E nicotinate, manganese ascorbate, zinc, oleyl alc., polysorbate 80, spermaceti, glycerol monostearate, beeswax, silicone oil, paraffin wax, ozokerite, and PEG 75 lanolin.

IT 50-21-5, biological studies 72-17-3, Sodium lactate
 77-92-9, biological studies 29031-19-4, Glucosamine sulfate.
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical compns. containing lecithins and moisturizers for treatment skin disorders)


RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 72-17-3 HCAPLUS


CN Propanoic acid, 2-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 77-92-9 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9


CMF H₂ O₄ S

CM 2

CRN 3416-24-8

CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:672448 HCAPLUS

DOCUMENT NUMBER: 129:280777

TITLE: Topical moisturizing composition containing water-dispersible lecithin

INVENTOR(S): Crandall, Wilson T.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842309	A1	19981001	WO 1998-US5910	19980325
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,			

GA, GN, ML, MR, NE, SN, TD, TG
AU 9725503 A1 19981020 AU 1997-25503 19970325
US 5945409 A 19990831 US 1997-876764 19970616
AU 9867750 A1 19981020 AU 1998-67750 19980325
PRIORITY APPLN. INFO.: US 1997-876764 A 19970616
US 1995-403241 A2 19950310
WO 1997-US4985 A 19970325
WO 1998-US5910 W 19980325


AB Methods and compns. for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves and horns are disclosed. The methods and compns. comprise applying to the keratinous tissue a water-dispersible lecithin. A solution of 20 g soy lecithin in 20 mL iso-Pr palmitate was mixed with 2 mL of almond oil and 80 mL of 20% Pluronic solution to obtain a gel. The moisturizing effect of the gel on the skin of volunteers was studied.

IT 50-21-5, Lactic acid, biological studies 72-17-3, Sodium lactate 77-92-9, Citric acid, biological studies
29031-19-4, Glucosamine sulfate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(topical moisturizing composition containing water-dispersible lecithin)
RN 50-21-5 HCAPLUS
CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 72-17-3 HCAPLUS
CN Propanoic acid, 2-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 77-92-9 HCAPLUS
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 29031-19-4 HCAPLUS
CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 29 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:184340 HCPLUS

DOCUMENT NUMBER: 128:263984

TITLE: Photosensitive resin composition containing carbohydrates, its cured product, and ink-jet receptor, etc. coated with the composition

INVENTOR(S): Yoshida, Kenji; Tokuda, Hiroyisa; Ishii, Kazuhiko

PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10077309	A2	19980324	JP 1996-246960	19960830
PRIORITY APPLN. INFO.:			JP 1996-246960	19960830

AB The composition contains (A) ethylenically-unsatd. compound, (B) carbohydrates, preferably chitosan lactate, (C) a photoinitiator, and (D) a filler as essential components, and optionally (E) a polymer having tertiary N. Also claimed are a cured product of the composition and materials coated with the cured film, e.g. ink-jet printing paper, OHP sheet, optical disks, etc. The ink jet printing paper having an ink-receptive layer comprising the composition shows good ink drying, image stability, transferability, and anticurling property.


IT 29031-19-4, Glucosamine sulfate 66267-50-3, Chitosan lactate

RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
 (photocurable resin composition containing chitosan (salts) for ink-jet printing sheet)

RN 29031-19-4 HCPLUS
 CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
 CMF H₂ O₄ S



CM 2

CRN 3416-24-8
 CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



RN 66267-50-3 HCPLUS
 CN Chitosan, 2-hydroxypropanoate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 9012-76-4
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 50-21-5
 CMF C₃ H₆ O₃



L20 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1997:411064 HCAPLUS
 DOCUMENT NUMBER: 127:85838
 TITLE: Topical moisturizing composition containing lecithin and isopropyl palmitate
 INVENTOR(S): Crandall, Wilson Trafton
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 5 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5639740	A	19970617	US 1995-403241	19950310
WO 9842348	A1	19981001	WO 1997-US4985	19970325
W: AU, CA, JP RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9725503	A1	19981020	AU 1997-25503	19970325
US 5945409	A	19990831	US 1997-876764	19970616
US 6316428	B1	20011113	US 1999-383779	19990826
PRIORITY APPLN. INFO.:			US 1995-403241	A 19950310
			WO 1997-US4985	A 19970325
			US 1997-876764	A1 19970616


AB Topical moisturizing composition for treating keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns contain lecithin and iso-Pr palmitate. Lecithin organogel was prepared by dissolving 20 g of soy lecithin granules in 20 mL of iso-Pr palmitate. This lecithin organogel was topically applied in cream form to the skin of one hand of volunteers with a history of dry skin. The treated skin appeared smoother, softer and younger and many cracks disappeared after 10 day treatment.

IT 50-21-5, Lactic acid, biological studies 77-92-9, Citric acid, biological studies 29031-19-4, Glucosamine sulfate
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)


(topical moisturizing composition containing lecithin and iso-Pr palmitate)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 77-92-9 HCAPLUS
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)




RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H2 O4 S




CM 2

CRN 3416-24-8

CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:147938 HCAPLUS

DOCUMENT NUMBER: 120:147938

TITLE: Second-order nonlinear optical properties of saccharide materials

AUTHOR(S): Bourhill, Grant; Mansour, Kamjou; Perry, Kelly J.; Khundkar, Lutfur; Sleva, Edward T.; Kern, Roger; Perry, Joseph W.; Williams, Ian D.; Kurtz, Stewart K.

CORPORATE SOURCE: Jet Propul. Lab., California Inst. Technol., Pasadena, CA, 91109, USA

SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (1993), 1853(Organic and Biological Optoelectronics), 110-25
CODEN: PSISDG; ISSN: 0277-786X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Saccharide materials are potential candidates for frequency conversion applications. In addition to being chiral, which ensures crystallization in a space

group relevant for 3-wave mixing processes, they generally possess useful phys. and optical properties. The powder 2nd-harmonic generation efficiencies of both saturated saccharides and sugars with simple polar π -functionalities were examined. Powder efficiencies of ≤ 5 times that of sucrose were observed for simple saturated sugars, whereas values of 18 + sucrose (or 0.45 + urea) were observed for unsatd. saccharide derivs. For both classes of material, there is a tendency for more

efficient nonlinear compds. to reside in a monoclinic rather than an orthorhombic space group. There apparently is a correlation between the phase-matching potential and the crystal symmetry.


IT 299-27-4, Potassium D-Gluconate 527-07-1, Sodium D-Gluconate 29031-19-4, D-Glucosamine Sulfate

RL: PRP (Properties)
(nonlinear optical property of, second-harmonic generation)

RN 299-27-4 HCAPLUS

CN D-Gluconic acid, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 527-07-1 HCAPLUS

CN D-Gluconic acid, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9


CMF H₂ O₄ S



CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



L20 ANSWER 32 OF 32 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1993:591301 HCPLUS

DOCUMENT NUMBER: 119:191301

TITLE: Powder second harmonic generation efficiencies of saccharide materials

AUTHOR(S): Bourhill, Grant; Mansour, Kamjou; Perry, Kelly J.; Khundkar, Lutfur; Sleva, Edward T.; Kern, Roger; Perry, Joseph W.; Williams, Ian D.; Kurtz, Stewart K.

CORPORATE SOURCE: Jet Propul. Lab., California Inst. Technol., Pasadena, CA, 91109, USA

SOURCE: Chemistry of Materials (1993), 5(6), 802-8
CODEN: CMATEX; ISSN: 0897-4756

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Saccharide materials are potential candidates for frequency conversion applications. In addition to being chiral, which ensures crystallization in a space

group necessary for three-wave mixing processes, they generally possess useful phys. and optical properties. The authors examined the powder second harmonic generation efficiencies of both saturated saccharides and sugars with simple polar π -functionalities. Powder efficiencies of up to 5 times that of sucrose were observed for simple saturated sugars, whereas values of 18 times sucrose (or 0.45 + urea) were observed for unsatd. saccharide derivs. The authors noted that for both classes of material, there is a tendency for more efficient nonlinear compds. to reside in a monoclinic rather than an orthorhombic space group. The authors also noted that there appears to be a correlation between the phase-matching potential and the crystal symmetry. In addition, two promising saccharide materials have been identified for frequency conversion applications, based on their powder second-harmonic generation efficiencies, their phase-matching capabilities, and their UV transparency.

IT 299-27-4, Potassium D-gluconate 527-07-1, Sodium D-gluconate 29031-19-4, D-Glucosamine sulfate


RL: USES (Uses)

(powder second harmonic generation efficiency of)

RN 299-27-4 HCPLUS

CN D-Gluconic acid, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 527-07-1 HCAPLUS

CN D-Gluconic acid, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


RN 29031-19-4 HCAPLUS

CN D-Glucose, 2-amino-2-deoxy-, sulfate (salt) (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 7664-93-9

CMF H₂ O₄ S




CM 2

CRN 3416-24-8

CMF C₆ H₁₃ N O₅

Absolute stereochemistry. Rotation (+).



Krishnan 09/926,821

June 25, 2004

This Page Blank (uspto)